tore at

Phospho-p53 Antibody Sampler Kit



Support: +1-978-867-2388 (U.S.) www.cellsignal.com/support

Orders: 877-616-2355 (U.S.) orders@cellsignal.com

#65390

New 11/19

For Research Use Only. Not For Use In Diagnostic Procedures.

Products Included	Product #	Quantity	Mol. Wt.	Isotype/Source
Phospho-p53 (Ser6) Antibody	9285	20 μΙ	53 kDa	Rabbit
Phospho-p53 (Ser9) Antibody	9288	20 μΙ	53 kDa	Rabbit
Phospho-p53 (Ser15) (16G8) Mouse mAb	9286	20 μΙ	53 kDa	Mouse IgG1
Phospho-p53 (Ser20) Antibody	9287	20 μΙ	53 kDa	Rabbit
Phospho-p53 (Ser46) Antibody	2521	20 μΙ	53 kDa	Rabbit
Phospho-p53 (Thr81) Antibody	2676	20 μΙ	53 kDa	Rabbit
Phospho-p53 (Ser392) Antibody	9281	20 μΙ	53 kDa	Rabbit
p53 (7F5) Rabbit mAb	2527	20 μΙ	53 kDa	Rabbit IgG
Anti-rabbit IgG, HRP-linked Antibody	7074	100 μΙ		Goat

See www.cellsignal.com for individual component applications, species cross-reactivity, dilutions and additional application protocols.

Description: The Phospho-p53 Antibody Sampler Kit provides a fast and economical means of evaluating multiple phosphorylation sites of p53 protein. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.

Background: The p53 tumor suppressor protein plays a major role in cellular response to DNA damage and other genomic aberrations. Activation of p53 can lead to either cell cycle arrest and DNA repair or apoptosis (1). p53 is phosphorylated at multiple sites in vivo and by several different protein kinases in vitro (2,3). DNA damage induces phosphorylation of p53 at Ser15 and Ser20 and leads to a reduced interaction between p53 and its negative regulator, the oncoprotein MDM2 (4). MDM2 inhibits p53 accumulation by targeting it for ubiquitination and proteasomal degradation (5,6). p53 can be phosphorylated by ATM, ATR, and DNA-PK at Ser15 and Ser37. Phosphorylation impairs the ability of MDM2 to bind p53, promoting both the accumulation and activation of p53 in response to DNA damage (4,7). Chk2 and Chk1 can phosphorylate p53 at Ser20, enhancing its tetramerization, stability, and activity (8,9). p53 is phosphorylated at Ser392 in vivo (10,11) and by CAK in vitro (11). Phosphorylation of p53 at Ser392 is increased in human tumors (12) and has been reported to influence the growth suppressor function, DNA binding, and transcriptional activation of p53 (10,13,14), p53 is phosphorylated at Ser6 and Ser9 by CK 1δ and CK1ε both in vitro and in vivo (13,15). Phosphorylation of p53 at Ser46 regulates the ability of p53 to induce apoptosis (16). Acetylation of p53 is mediated by p300 and CBP acetyltransferases. Inhibition of deacetylation suppressing MDM2 from recruiting HDAC1 complex by p19 (ARF) stabilizes p53. Acetylation appears to play a positive role in the accumulation of p53 protein in stress response (17). Following DNA damage, human p53 becomes acetylated at Lys382 (Lys379 in mouse) in vivo to enhance p53-DNA binding (18). Deacetylation of p53 occurs through interaction with the SIRT1 protein, a deacetylase that may be involved in cellular aging and the DNA damage response (19).

Specificity/Sensitivity: Phospho-p53 (Ser6), (Ser9), (Ser15), (Ser20), (Ser46), (Thr81), and (Ser392) Antibodies detect p53 only when phosphorylated at the indicated sites and do not cross-react with p53 phosphorylated at other sites. p53 (7F5) Rabbit mAb detects endogenous levels of total p53 protein.

Source/Purification: Polyclonal antibodies are produced by immunizing animals with a synthetic peptide and are purified by protein A and peptide affinity chromatography. Monoclonal antibodies are produced by immunizing animals with recombinant human proteins or synthetic peptides.

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μ g/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20° C. Do not aliquot the antibodies.

Please visit www.cellsignal.com for validation data and a complete listing of recommended companion products.

Background References:

- (1) Levine, A.J. (1997) Cell 88, 323-31.
- (2) Meek, D.W. (1994) Semin Cancer Biol 5, 203-10.
- (3) Milczarek, G.J. et al. (1997) Life Sci 60, 1-11.
- (4) Shieh, S.Y. et al. (1997) Cell 91, 325-34.
- (5) Chehab, N.H. et al. (1999) Proc Natl Acad Sci U S A 96, 13777-82.
- (6) Honda, R. et al. (1997) FEBS Lett 420, 25-7.
- (7) Tibbetts, R.S. et al. (1999) Genes Dev 13, 152-7.
- (8) Shieh, S.Y. et al. (1999) EMBO J 18, 1815-23.
- (9) Hirao, A. et al. (2000) Science 287, 1824-7.
- (10) Hao, M. et al. (1996) J Biol Chem 271, 29380-5.
- (11) Lu, H. et al. (1997) Mol Cell Biol 17, 5923-34.
- (12) Ullrich, S.J. et al. (1993) *Proc Natl Acad Sci U S A* 90, 5954-8
- (13) Kohn, K.W. (1999) Mol Biol Cell 10, 2703-34.
- (14) Lohrum, M. and Scheidtmann, K.H. (1996) *Oncogene* 13, 2527-39
- (15) Knippschild, U. et al. (1997) Oncogene 15, 1727-36.
- (16) Oda, K. et al. (2000) Cell 102, 849-62.
- (17) Ito, A. et al. (2001) EMBO J 20, 1331-40.
- (18) Sakaguchi, K. et al. (1998) Genes Dev 12, 2831-41.
- (19) Solomon, J.M. et al. (2006) Mol Cell Biol 26, 28-38.

U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.

Thank you for your recent purchase. If you would like to provide a review visit cellsignal.com/comments.

www.cellsignal.com

© 2019 Cell Signaling Technology, Inc.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.